Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Johnstone, Scott
CYPRESS, NCT05696717: Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic NOH in Participants with Multiple System Atrophy	Recruiting	3	102	Europe, Canada, US, RoW	Ampreloxetine, TD-9855, Placebo	Theravance Biopharma	Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy	12/24	01/27
NCT05526391 / 2022-000336-28: A Study of TAK-341 in Treatment of Multiple System Atrophy	Active, not recruiting	2	159	Europe, Japan, US	TAK-341, MEDI1341, Placebo	Takeda, AstraZeneca	Multiple System Atrophy	07/25	07/25